Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.7K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postprandial Hypotension-Methods for the Evaluation and Management.

Geriatrics & gerontology international·2026
Same author

Progression of exaggerated blood pressure variability in annual 24-h ambulatory blood pressure monitoring associated with autonomic dysfunction: a pathological case report.

Journal of hypertension·2026
Same author

Impaired sensitivity to thyroid hormones is associated with frailty in older patients with cardiometabolic disease.

BMC geriatrics·2025
Same author

Comparison of Predictive Ability of Clinical Frailty Scale, Kihon Checklist, and DASC-8 for New Certification of Long-Term Care Needs: A Longitudinal Study.

Geriatrics & gerontology international·2025
Same author

Area of center of pressure in closed eye setting as a measure of postural sway: Association with frailty and functional capacity in older adults with diabetes.

PloS one·2025
Same author

High red blood cell distribution width associated with incident frailty in patients with cardiometabolic diseases: A longitudinal study.

Scientific reports·2025

Related Experiment Video

Updated: Apr 25, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.7K

[Alpha blocker x beta-blocker].

Joji Ishikawa, Kazuomi Kario

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |August 30, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Bedtime administration of antihypertensive drugs like calcium channel blockers or angiotensin II receptor blockers is recommended for daily blood pressure control. Alpha-blockers or beta-blockers are considered last-line options for this regimen.

    More Related Videos

    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
    08:32

    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

    Published on: December 18, 2014

    25.3K
    Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
    10:26

    Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

    Published on: August 18, 2014

    25.7K

    Related Experiment Videos

    Last Updated: Apr 25, 2026

    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
    05:25

    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

    Published on: August 14, 2019

    19.7K
    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
    08:32

    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

    Published on: December 18, 2014

    25.3K
    Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
    10:26

    Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

    Published on: August 18, 2014

    25.7K

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Chronotherapy

    Context:

    • Managing hypertension requires optimizing drug timing for sustained 24-hour blood pressure control.
    • Bedtime dosing is an emerging strategy to improve therapeutic efficacy and patient adherence.

    Purpose:

    • To establish evidence-based guidelines for selecting antihypertensive medications for nighttime administration.
    • To identify first-line and last-choice drug classes for bedtime use in hypertension management.

    Summary:

    • Calcium channel blockers and angiotensin II receptor blockers are identified as preferred first-line agents for bedtime administration to control blood pressure.
    • Alpha-blockers and beta-blockers are recommended as alternative, last-choice options for nighttime dosing.

    Impact:

    • Provides clinicians with a clear framework for bedtime antihypertensive therapy selection.
    • Aims to improve daily blood pressure management and reduce cardiovascular event risk through optimized chronotherapy.